0RK.SG - Exscientia plc
Exscientia plc
The SchrOedinger Building
Oxford Science Park
Oxford OX4 4GE
United Kingdom
44 18 6581 8941
https://www.exscientia.ai
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 481
Key executives
| Name | Title | Pay | Exercised | Year born |
|---|---|---|---|---|
| Prof. Andrew L. Hopkins DPHIL, FRSE FRSC | Founder, CEO & Exec. Director | 670.2k | N/A | 1973 |
| Mr. Ben R. Taylor | CFO, Chief Strategy Officer & Exec. Director | 469.79k | N/A | 1977 |
| Dr. Garry Pairaudeau Ph.D. | Chief Technology Officer | N/A | N/A | 1967 |
| Dr. David Hallett Ph.D. | Chief Scientific Officer | N/A | N/A | 1971 |
| Dr. Michael Krams M.D. | Chief Quantitative Medicine Officer | N/A | N/A | 1961 |
| Ms. Margo Mosley | VP of Facilities & Operations | N/A | N/A | N/A |
| Ms. Eileen Jennings-Brown | Chief Information Officer | N/A | N/A | N/A |
| Ms. Sara Sherman | VP of Investor Relations | N/A | N/A | N/A |
| Mr. Dan Ireland | VP of Legal | N/A | N/A | N/A |
| Mr. Oliver Stohlmann | VP of Communications | N/A | N/A | N/A |
Description
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. It also focuses on discovery and development of small molecule drug candidates. The company's platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Corporate governance
Exscientia plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.
